1182 related articles for article (PubMed ID: 15707700)
1. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer.
Macaskill EJ; Renshaw L; Dixon JM
Oncologist; 2006; 11(10):1081-8. PubMed ID: 17110627
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant endocrine treatment in primary breast cancer - review of literature.
Mathew J; Asgeirsson KS; Jackson LR; Cheung KL; Robertson JF
Breast; 2009 Dec; 18(6):339-44. PubMed ID: 19836953
[TBL] [Abstract][Full Text] [Related]
4. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Barnadas A; Gil M; Sánchez-Rovira P; Llombart A; Adrover E; Estevez LG; de la Haba J; Calvo L
Anticancer Drugs; 2008 Apr; 19(4):339-47. PubMed ID: 18454044
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
7. [Neoadjuvant endocrine therapy for locally advanced breast cancer].
Viola G; Sergi D; Conti F; Lopez M
Clin Ter; 2007; 158(5):441-52. PubMed ID: 18062352
[TBL] [Abstract][Full Text] [Related]
8. Challenges in the endocrine management of breast cancer.
Mouridsen HT; Rose C; Brodie AH; Smith IE
Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant use of endocrine therapy in breast cancer.
Macaskill EJ; Dixon JM
Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
[TBL] [Abstract][Full Text] [Related]
10. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
12. Surgical issues surrounding use of aromatase inhibitors.
Dixon JM; Renshaw L; Murray J; Macaskill EJ; Young O; Miller WR
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):97-103. PubMed ID: 16023854
[TBL] [Abstract][Full Text] [Related]
13. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?
Takei H; Kurosumi M; Yoshida T; Hayashi Y; Higuchi T; Uchida S; Ninomiya J; Oba H; Inoue K; Nagai S; Tabei T
Breast Cancer; 2011 Apr; 18(2):85-91. PubMed ID: 21104350
[TBL] [Abstract][Full Text] [Related]
15. Letrozole in the neoadjuvant setting: the P024 trial.
Ellis MJ; Ma C
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):33-43. PubMed ID: 17912634
[TBL] [Abstract][Full Text] [Related]
16. Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
Cianfrocca M; Wolff AC
Oncology (Williston Park); 2007 Jan; 21(1):63-9; discussion 69, 72, 75 passim. PubMed ID: 17313157
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Arora A; Potter JF
J Am Geriatr Soc; 2004 Apr; 52(4):611-6. PubMed ID: 15066080
[TBL] [Abstract][Full Text] [Related]
18. [Neoadjuvant endocrine therapy for breast cancer: an overview].
Domont J; Namer M; Khayat D; Spano JP
Bull Cancer; 2004 Jan; 91(1):55-62. PubMed ID: 14975805
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
Iwata H
Breast Cancer; 2011 Apr; 18(2):92-7. PubMed ID: 21140250
[TBL] [Abstract][Full Text] [Related]
20. [Controversies in endocrine therapy for breast cancer].
Kawakami M; Saji S; Toi M
Gan To Kagaku Ryoho; 2004 Feb; 31(2):181-7. PubMed ID: 14997748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]